KV7 Potassium Channels: a Focus on Human Intra-Pulmonary Arteries

KV7 Potassium Channels: a Focus on Human Intra-Pulmonary Arteries

KV7 potassium channels: A focus on human intra-pulmonary arteries A thesis submitted to the University of Manchester for the degree of Doctor of Philosophy in the Faculty of Life Sciences 2015 Sean Brennan 1 List of contents Chapter 1 : Introduction ........................................................................................................ 15 1.1 Anatomy and physiology of the lungs .......................................................................... 15 1.2 Pulmonary artery structure ......................................................................................... 15 1.3 Pulmonary hypertension .............................................................................................. 16 1.3.1 Definition .............................................................................................................. 16 1.3.2 Characteristics ....................................................................................................... 17 1.3.3 Classification ......................................................................................................... 17 1.3.4 Treatment ............................................................................................................. 19 1.4 Regulation of the pulmonary vasculature.................................................................... 21 1.4.1 Neuronal regulation .............................................................................................. 21 1.4.2 Humoral regulation ............................................................................................... 22 1.4.3 Respiratory gases and the pulmonary artery ........................................................ 24 1.5 Calcium and contraction .............................................................................................. 25 1.6 Pulmonary artery smooth muscle cells and membrane potential .............................. 28 1.7 Pulmonary artery smooth muscle cell proliferation. ............................................... 29 1.8 Pulmonary artery smooth muscle cell migration. .................................................... 30 1.9 Potassium ion channels in pulmonary artery smooth muscle ..................................... 31 1.10 Potassium channel involvement in regulating the membrane potential of pulmonary artery smooth muscle ........................................................................................................ 36 1.10.1 KATP (KIR6.1) channels ........................................................................................... 36 2+ + 1.10.2 Large-conductance Ca -activated K (BKCa) channels ........................................ 37 + 1.10.3 Voltage-gated K (KV) channels ........................................................................... 38 1.10.4 Two-pore domain channels ................................................................................ 39 1.10.5 Two alternative hypotheses to explain the resting potential of PASMC. ........... 39 1.10.5.1 Hypothesis 1- KV1.5 and KV2.1 set the resting membrane potential in pulmonary artery smooth muscle cells. ..................................................................... 40 2 1.10.5.2 Hypothesis 2: The KV7 sub-family and TASK channels set the resting membrane potential in pulmonary artery smooth muscle cells. .............................. 40 1.11 K+ channels and pulmonary artery smooth muscle cell proliferation, apoptosis and migration. ........................................................................................................................... 42 1.12 Molecular diversity in KV7 channels ........................................................................... 44 1.12.1 KCNQ Splice Variants........................................................................................... 48 1.12.2 KCNE1-5 auxiliary subunits ................................................................................. 48 1.13 Expression and the physiological roles of KV7 channels ............................................ 50 1.13.1 KV7 channels in vascular smooth muscle ............................................................ 51 1.14 KV7 channel Pharmacology .................................................................................... 53 1.14.1 KV7 channel blockers ....................................................................................... 53 1.14.2 KV7 channel activators .................................................................................... 55 1.15 Project aims ............................................................................................................... 59 1.16 Alternative format ..................................................................................................... 60 Chapter 2 : Functional role for KV7 potassium channels in human pulmonary artery .......... 63 2.1 Abstract ........................................................................................................................ 64 2.2 Introduction ................................................................................................................. 64 2.3 Methods ....................................................................................................................... 66 2.3.1 Human Tissue samples .......................................................................................... 66 2.3.2 Rat pulmonary arteries ......................................................................................... 68 2.3.3 Measurement of mRNA Expression ...................................................................... 68 2.3.3.1 RNA isolation .................................................................................................. 68 2.3.3.2 RNA integrity .................................................................................................. 69 2.3.3.3 cDNA synthesis ............................................................................................... 70 2.3.3.4 End-point PCR ................................................................................................ 70 2.3.3.5 Quantitative RT-PCR ....................................................................................... 71 2.3.3.6 Primers ........................................................................................................... 71 3 2.3.3.7 Primer Efficiency ........................................................................................... 73 2.3.3.8 qRT-PCR normalisation .................................................................................. 74 2.3.4 Western blot ......................................................................................................... 76 2.3.5 Myography ............................................................................................................ 77 2.3.5.1 Mounting vessels ........................................................................................... 77 2.3.5.2 Normalisation protocol .................................................................................. 78 2.3.5.3 Vessel validation protocol .............................................................................. 79 2.3.5.4 Endothelium integrity .................................................................................... 79 2.3.5.5 Experimental protocols for KV7 blockers ....................................................... 80 2.3.5.6 Experimental protocols for KV7 activators ..................................................... 80 2.3.6 Drugs ..................................................................................................................... 81 2.3.7 Data analysis ......................................................................................................... 81 2.4 Results .......................................................................................................................... 82 2.4.1 RNA quality ........................................................................................................... 82 2.3.2.8 Primer Efficiency and specificity .................................................................... 82 2.4.2 Housekeeping gene selection ............................................................................... 85 2.4.3 KV7 channel expression in human intra-pulmonary and omental arteries ........... 87 2.4.4 Endothelium integrity ........................................................................................... 91 2.4.5 Effects of KV7 channel blockers on human intra-pulmonary artery tone ............. 93 2+ 2.4.6 Constriction induced by KV7 channel blockers requires voltage-gated Ca influx. ....................................................................................................................................... 95 2.4.7 Dilator effects of KV7 channel activators on human intra-pulmonary and omental arteries. .......................................................................................................................... 97 2.4.8 Retigabine acts via membrane hyperpolarisation and inhibition of voltage-gated Ca2+ influx ....................................................................................................................... 99 2.5 Discussion ................................................................................................................... 102 2.5.1 KV7 channels expressed in human iPAs ............................................................... 102 4 2.5.2 KCNE expression ................................................................................................

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    224 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us